Company Overview and News

to your dashboard

Headline News

Can Valeant (VRX) Turn Around on Rebuilding Initiatives?

14h zacks
Shares of Valeant Pharmaceuticals International Inc. (VRX - Free Report) have rallied 7.2% year to date compared with the industry’s gain of 2.4%. (242-2)

Mallinckrodt (MNK) Down 55% Year to Date: What Lies Ahead?

2017-11-20 zacks
Shares of Mallinckrodt plc (MNK - Free Report) have tumbled 55.1% year to date, compared with the industry’s decline of 29.2%. (46-0)

Roche Reports Positive Data From Tecentriq Combination Study

2017-11-20 zacks
Roche Holding AG’s (RHHBY - Free Report) member, Genentech, announced that the phase III IMpower150 study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy (carboplatin and paclitaxel), with or without Avastin has met its co-primary endpoint of progression-free survival (PFS). The study is being conducted  in people with stage IV non-squamous non-small cell lung cancer (NSCLC), who had not been treated with chemotherapy for their advanced disease. (51-0)

Alnylam Starts Rolling NDA Submission for RNAi Candidate

2017-11-17 zacks
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced that it has initiated submission of a rolling New Drug Application (NDA) to the FDA for lead candidate patisiran. The candidate is an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of hereditary ATTR (hATTR) amyloidosis.  The rolling submission allows completed portions of an NDA to be reviewed by the FDA on an ongoing basis. (49-0)

Incyte (INCY) Initiates Essential Thrombocythemia Trial

2017-11-16 zacks
Incyte Corporation (INCY - Free Report) recently announced that the first patient has been treated in the RESET trial on ruxolitinib. (58-0)

Valeant (VRX) Announces Pricing of Senior Secured Notes

2017-11-15 zacks
Valeant Pharmaceuticals International, Inc. (VRX - Free Report) announced that it has priced its previously announced offering of $750,000,000 aggregate principal amount of 5.500% senior secured notes due 2025. These will be additional notes and form part of the same series as the existing 5.500% senior secured notes due 2025.Valeant will sell the notes at a price of 100.0% of the principal amount thereof plus accrued interest from Oct 17, 2017. (201-0)

Roche (RHHBY) Receives FDA Clearance for Ventana MMR Test

2017-11-15 zacks
Roche Holdings AG (RHHBY - Free Report) recently announced FDA clearance for the VENTANA MMR IHC Panel for immunohistochemistry (IHC) tests on colorectal cancer patients. (39-0)

Pacira's Exparel sNDA to be Reviewed by FDA Advisory Committee

2017-11-15 zacks
Shares of Pacira Pharmaceuticals, Inc. (PCRX - Free Report) declined about 6.6% on Nov 14. This followed the FDA’s notice stating that the company’s supplemental New Drug Application (sNDA) for  label expansion of Exparel (bupivacaine liposome injectable suspension) in the nerve block setting will be discussed at a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (“AADPAC”) before a final decision. (49-0)

Cardinal Health (CAH) to Divest Assets to Shanghai Pharma

2017-11-15 zacks
Cardinal Health Inc. (CAH - Free Report) recently agreed to sell Cardinal Health China business to Shanghai Pharmaceuticals Holding Co. Ltd. for $1.2 billion. The sale includes Cardinal Health's pharmaceutical and medical products distribution business in China. (117-0)

Glaxo's Subcutaneous Formulation of Benlysta Approved in EU

2017-11-14 zacks
GlaxoSmithKline plc (GSK - Free Report) announced approval in EU for a new self-injectable subcutaneous ("SC") formulation of Benlysta for systemic lupus erythematosus ("SLE"). The subcutaneous formulation is already approved in the United States. (101-0)

Alnylam RNAi Drug Gets Accelerated Assessment Grant From EMA

2017-11-14 zacks
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has granted an accelerated assessment for patisiran. (72-0)

Shire Gets Positive CHMP Opinion for Hemophilia A Drug

2017-11-14 zacks
Shire plc (SHPG - Free Report) announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has issued a positive opinion recommending approval  of Adynovi [Antihemophilic Factor (Recombinant), PEGylated]. (73-0)

Macy's, Nordstrom, Kohl's, J.C. Penney and Amazon are part of Zacks Earnings Preview

2017-11-13 zacks
Chicago, IL – Nov 13, 2017 – releases the list of companies likely to issue earnings surprises. This week’s list includes Macy’s (M - Free Report) , Nordstrom (JWN - Free Report) , Kohl’s (KSS - Free Report) , J.C. Penney (JCP - Free Report) and Amazon (AMZN - Free Report) . (850-3) highlights: Rosetta Stone, Nova Measuring Instruments and Yaskawa Electric

2017-11-13 zacks
Chicago, IL – November 13, 2017 - Stocks in this week’s article include: Rosetta Stone Inc. (RST - Free Report) , Nova Measuring Instruments Ltd. (NVMI - Free Report) and Yaskawa Electric Corporation (YASKY - Free Report) . (818-0)

Twin Disc, Impinji,, Home Depot and Walmart Stores highlighted as Zacks Bull and Bear of the Day

2017-11-13 zacks
Chicago, IL – Nov 13, 2017 – Zacks Equity Research highlights Twin Disc, Inc. (TWIN - Free Report) as the Bull of the Day and Impinji Inc. (PI - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on the, Inc. (JD - Free Report) , Home Depot, Inc. (HD - Free Report) and Walmart Stores, Inc. (WMT - Free Report) . (862-1)

CUSIP: 218352102